TLIS · Talis Biomedical Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $73.0K | - | $140.0K | $581.0K | $1.22M | - | $796.0K | $572.0K | $3.19M |
| Cost of Revenue | $0 | $6.0K | - | $6.0K | $7.0K | $20.0K | - | $0 | $1.30M | $0 |
| Gross Profit | $0 | $67.0K | - | $134.0K | $574.0K | $1.20M | - | ($440.0K) | ($730.0K) | $7.00M |
| R&D | $1.60M | $2.53M | - | $8.30M | $10.55M | $13.80M | - | $17.52M | $17.36M | $20.70M |
| SG&A | $7.98M | $11.65M | - | $8.80M | $6.41M | $6.40M | - | $8.82M | $9.18M | $11.93M |
| Total Operating Expenses | $9.58M | $14.19M | - | $17.11M | $27.84M | $36.15M | - | $26.35M | $26.54M | $32.63M |
| D&A | - | $262.0K | - | - | - | $174.0K | - | $3.30M | - | $363.0K |
| Operating Income | ($9.58M) | ($14.12M) | - | ($16.97M) | ($16.39M) | ($19.00M) | - | ($26.79M) | ($27.27M) | ($32.97M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($8.85M) | ($13.04M) | - | ($15.68M) | ($15.03M) | ($17.83M) | - | ($26.02M) | ($27.01M) | ($33.05M) |
| EPS - Basic | ($4.86) | ($7.15) | - | ($8.62) | ($8.27) | ($1.25) | - | ($1.49) | - | - |
| EPS - Diluted | ($4.86) | ($7.15) | - | ($8.62) | ($15.01) | ($0.66) | - | ($1.49) | - | - |
Balance Sheet
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $59.87M | $70.34M | $76.73M | $88.00M | $98.20M | $112.96M | $130.19M | $143.78M | $165.37M | $187.59M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | $2.03M | $2.22M | $0 |
| Accounts Payable | $3.79M | $3.62M | $1.34M | $2.70M | $2.49M | $3.87M | $3.77M | $4.11M | $3.98M | $5.26M |
| Current Assets | $63.60M | $71.17M | $77.68M | $89.53M | $101.97M | $115.59M | $133.28M | $150.38M | $173.97M | $200.82M |
| Total Assets | $72.70M | $82.49M | $94.67M | $107.23M | $123.08M | $133.05M | $169.29M | $194.09M | $221.69M | $230.59M |
| Current Liabilities | $8.20M | $9.47M | $8.77M | $8.45M | $9.26M | $11.18M | $12.67M | $11.38M | $13.90M | $15.28M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $24.07M | $25.81M | $25.56M | $25.67M | $26.91M | $22.93M | $42.55M | $41.71M | $44.67M | $27.80M |
| Stockholders' Equity | $48.63M | $56.68M | $69.12M | $81.56M | $96.17M | $110.12M | $126.74M | $152.39M | $177.02M | $202.78M |
| Retained Earnings | ($561.85M) | ($553.00M) | ($539.96M) | ($526.50M) | ($510.82M) | ($495.79M) | ($477.95M) | ($451.02M) | ($425.00M) | ($397.99M) |
Cash Flow
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($6.43M) | - | - | - | ($16.46M) | - | - | - | ($43.76M) |
| Investing Cash Flow | - | $30.0K | - | - | - | ($24.0K) | - | - | - | ($507.0K) |
| Financing Cash Flow | - | $2.0K | - | - | - | $33.0K | - | - | - | $314.0K |
| CapEx | - | $0 | - | - | - | $24.0K | - | - | - | $507.0K |
| Free Cash Flow | - | ($6.43M) | - | - | - | ($16.49M) | - | - | - | ($44.27M) |
Ratios
| Metric | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 91.8% | - | 95.7% | 98.8% | 98.4% | - | -55.3% | -127.6% | 219.6% |
| Operating margin | - | -19338.4% | - | -12122.1% | -2821.2% | -1559.7% | - | -3365.1% | -4768.0% | -1034.4% |
| EBITDA margin | - | -18979.5% | - | - | - | -1545.4% | - | -2950.5% | - | -1023.0% |
| Net margin | - | -17856.2% | - | -11201.4% | -2587.6% | -1464.0% | - | -3269.0% | -4722.2% | -1037.1% |
| Free cash flow margin | - | -8804.1% | - | - | - | -1353.8% | - | - | - | -1388.9% |
| FCF / Net income | - | 0.49 | - | - | - | 0.92 | - | - | - | 1.34 |
| R&D / Revenue | - | 3469.9% | - | 5930.0% | 1816.7% | 1132.7% | - | 2201.1% | 3035.8% | 649.6% |
| SG&A / Revenue | - | 15960.3% | - | 6287.9% | 1103.3% | 525.4% | - | 1108.7% | 1604.5% | 374.3% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.2% | -15.8% | - | -14.6% | -12.2% | -13.4% | - | -13.4% | -12.2% | -14.3% |
| Return on equity | -18.2% | -23.0% | - | -19.2% | -15.6% | -16.2% | - | -17.1% | -15.3% | -16.3% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.76 | 7.51 | 8.86 | 10.60 | 11.01 | 10.34 | 10.52 | 13.22 | 12.51 | 13.15 |
| Quick ratio | 7.76 | 7.51 | 8.86 | 10.60 | 11.01 | 10.34 | 10.52 | 13.04 | 12.35 | 13.15 |
| Cash ratio | 7.30 | 7.43 | 8.75 | 10.41 | 10.60 | 10.10 | 10.27 | 12.64 | 11.89 | 12.28 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.50 | 1.46 | 1.37 | 1.31 | 1.28 | 1.21 | 1.34 | 1.27 | 1.25 | 1.14 |
| Liabilities / Assets | 0.33 | 0.31 | 0.27 | 0.24 | 0.22 | 0.17 | 0.25 | 0.21 | 0.20 | 0.12 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.01 | - | 0.00 | 0.00 | 0.01 |
| Inventory turnover | - | - | - | - | - | - | - | 0.00 | 0.59 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | 622d | - |
| Days payable outstanding | - | 220156d | - | 164068d | 129888d | 70646d | - | - | 1115d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -100.0% | -94.0% | - | -82.4% | 1.6% | -61.8% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | -94.4% | - | - | - | -82.9% | - | - | - | - |
| Operating income growth (YoY) | 41.6% | 25.7% | - | 36.6% | 39.9% | 42.4% | - | 30.3% | 57.6% | -345.8% |
| Net income growth (YoY) | 41.1% | 26.9% | - | 39.7% | 44.3% | 46.1% | - | 32.3% | -168.9% | -348.2% |
| EPS growth (YoY) | 67.6% | -983.3% | - | -478.5% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 61.0% | - | - | - | 62.7% | - | - | - | -676.4% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -49.4% | -48.5% | -45.5% | -46.5% | -45.7% | -45.7% | -45.8% | - | -39.7% | - |
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing Talis Biomedical Corp against the 5 most active filers in the same SIC group.